Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Failed Prior Novel Hormone Therapy

NCT06702995 is registered in ClinicalTrials.gov with Evopoint Biosciences Inc. as lead sponsor.

NCT NCT06702995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06702995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Failed Prior Novel Hormone Therapy
Lead sponsor
Evopoint Biosciences Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 19, 2023
Completion date
July 19, 2026
Enrollment
307 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mcrpc (metastatic castration-resistant prostate cancer), metastatic castrate-resistant prostate cancer